ELISpot检测脓毒症期间固有免疫和适应性免疫的时间变化
研究用亚致死性盲肠结扎穿孔制作小鼠脓毒症模型,系列采集血液和脾脏,用ELISpot与酶联免疫吸附试验比较离体干扰素γ和TNF-α产生,并评估ELISpot检测地塞米松、IL-7和精氨酸体内免疫治疗效应的能力。ELISpot证实脓毒症进展期间固有和适应性免疫反应性下降;ELISpot还能以可定量方式检测上述免疫调节剂引起的固有和适应性免疫变化,且与这些药物已知作用机制一致。ELISpot与酶联免疫吸附试验结果趋势平行,但存在一些差异。作者认为ELISpot能随时间评估固有和适应性免疫功能状态,并可用于检测和随访改善脓毒症诱导免疫功能障碍的药物的体内效应。
要点
- 小鼠亚致死性盲肠结扎穿孔脓毒症模型中,ELISpot证实脓毒症进展期间固有和适应性免疫反应性下降。
- ELISpot能以可定量方式检测地塞米松、精氨酸和IL-7引起的固有和适应性免疫变化,且与这些药物已知作用机制一致。
- ELISpot与酶联免疫吸附试验结果趋势平行,但存在一些差异。
- 作者认为ELISpot可随时间评估固有和适应性免疫功能状态,并检测和随访改善脓毒症诱导免疫功能障碍药物的体内效应。
适用人群与场景
- 小鼠亚致死性盲肠结扎穿孔脓毒症模型;系列采集血液和脾脏。
处置流程与药物剂量
- 体内免疫治疗评估药物包括地塞米松、IL-7和精氨酸;具体剂量、途径、频次及疗程原文未写明。
研究设计与关键结果
- 研究类型为小鼠实验;采用亚致死性盲肠结扎穿孔制作脓毒症模型,系列采集血液和脾脏,用ELISpot与酶联免疫吸附试验比较离体干扰素γ和TNF-α产生。
- ELISpot证实脓毒症进展期间固有和适应性免疫反应性下降。
- ELISpot检测到地塞米松、精氨酸和IL-7引起的固有和适应性免疫变化,结果与这些药物已知作用机制一致。
- ELISpot与酶联免疫吸附试验结果趋势平行,但存在一些差异。
证据类型、等级与局限
- 证据类型:动物实验(小鼠脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ELISpot能随时间评估固有和适应性免疫功能状态,并可用于检测和随访改善脓毒症诱导免疫功能障碍药物的体内效应;作者认为这一能力将是指导脓毒症新免疫治疗的一大进步。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: The inability to evaluate host immunity in a rapid quantitative manner in patients with sepsis has severely hampered development of novel immune therapies. The enzyme-linked immunospot (ELISpot) assay is a functional bioassay that measures the number of cytokine-secreting cells and the relative amount of cytokine produced at the single-cell level. A key advantage of ELISpot is its excellent dynamic range enabling a more precise quantifiable assessment of host immunity. Herein, we tested the hypothesis that the ELISpot assay can detect dynamic changes in both innate and adaptive immunity as they often occur during sepsis. We also tested whether ELISpot could detect the effect of immune drug therapies to modulate innate and adaptive immunity. Methods: Mice were made septic using sublethal cecal ligation and puncture. Blood and spleens were harvested serially, and ex vivo interferon γ and TNF-α production were compared by ELISpot and enzyme-linked immunosorbent assay. The capability of ELISpot to detect changes in innate and adaptive immunity due to in vivo immune therapy with dexamethasone, IL-7, and arginine was also evaluated. Results: ELISpot confirmed a decreased innate and adaptive immunity responsiveness during sepsis progression. More importantly, ELISpot was also able to detect changes in adaptive and innate immunity in response to immune-modulatory reagents, for example, dexamethasone, arginine, and IL-7, in a readily quantifiable manner, as predicted by the reagents known mechanisms of action. ELISpot and enzyme-linked immunosorbent assay results tended to parallel one another although some differences were noted. Conclusion: ELISpot offers a unique capability to assess the functional status of both adaptive and innate immunity over time. The results presented herein demonstrate that ELISpot can also be used to detect and follow the in vivo effects of drugs to ameliorate sepsis-induced immune dysfunction. This capability would be a major advance in guiding new immune therapies in sepsis.
参考来源
- Unsinger J, Osborne D, Walton AH, et al. TEMPORAL CHANGES IN INNATE AND ADAPTIVE IMMUNITY DURING SEPSIS AS DETERMINED BY ELISPOT. Shock. 2024. PMID: 38754032. doi:10.1097/SHK.0000000000002377
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。